SynthesisFrontiers in pharmacology2026
Efficacy and safety of nab-paclitaxel in advanced or recurrent small cell lung cancer: a single-arm meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although various effective agents used as second- and third-line treatments for advanced or recurrent small cell lung cancer have improved overall survival, the optimal therapeutic regimen remains controversial. Previous studies have shown that albumin-bound paclitaxel exhibits favorable anticancer activity in many cancer types. However, almost all studies of albumin-bound paclitaxel for recurrent small cell lung cancer are non-randomized controlled trials with small sample sizes, diverse first-line treatment regimens, and non-controlled data analyses. This may result in a lack of valid indicators for evaluating the efficacy and safety of albumin-bound paclitaxel. Therefore, this meta-analysis aims to assess the efficacy and safety of albumin-bound paclitaxel in patients with advanced or recurrent small cell lung cancer. Methods: PubMed, Embase, the Cochrane Library, and Web of Science databases were systematically searched for relevant studies. Outcomes including overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were extracted for further analysis. Results: Nine studies involving 334 patients were enrolled in this meta-analysis. In terms of tumor response, the pooled ORR and DCR were 25.0% and 62.5%, respectively. With regard to survival analysis, the pooled PFS and OS were 3.16 months and 7.23 months, respectively. The most common treatment-related adverse events of nab-paclitaxel were Leukopenia (all grade: 59.3%, ≥grade III: 14.1%), Neutropenia (all grade: 54.9%, ≥grade III: 14.7%), and Anemia (all grade: 53.0%, ≥grade III: 6.2%). Subgroup analysis revealed that combination therapy with immunotherapy was associated with numerically higher response rates and survival. Conclusions: In summary, this meta-analysis demonstrated that albumin-bound paclitaxel has moderate efficacy and manageable safety in the later-line treatment of advanced or recurrent small cell lung cancer. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261350933, identifier 420261350933.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.